545 related articles for article (PubMed ID: 7562498)
21. Reversal effects of Rabdosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro.
Li F; Fan J; Wu Z; Liu RY; Guo L; Dong Z; Wang Z
Pharm Biol; 2013 Sep; 51(9):1196-203. PubMed ID: 23777360
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
23. Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to P-glycoprotein.
Chen G; Ramachandran C; Krishan A
Cancer Res; 1993 Jun; 53(11):2544-7. PubMed ID: 8098661
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Walker J; Martin C; Callaghan R
Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
[TBL] [Abstract][Full Text] [Related]
25. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.
Xu D; Lu Q; Hu X
Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853
[TBL] [Abstract][Full Text] [Related]
27. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
29. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W
Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446
[TBL] [Abstract][Full Text] [Related]
30. Circumvention of tumor multidrug resistance by a new annonaceous acetogenin: atemoyacin-B.
Fu LW; Pan QC; Liang YJ; Huang HB
Zhongguo Yao Li Xue Bao; 1999 May; 20(5):435-9. PubMed ID: 10678092
[TBL] [Abstract][Full Text] [Related]
31. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.
Benchekroun MN; Schneider E; Safa AR; Townsend AJ; Sinha BK
Mol Pharmacol; 1994 Oct; 46(4):677-84. PubMed ID: 7969046
[TBL] [Abstract][Full Text] [Related]
33. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Abulrob AN; Mason M; Bryce R; Gumbleton M
J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
[TBL] [Abstract][Full Text] [Related]
34. Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil.
Ye W; Chang HL; Wang LS; Huang YW; Shu S; Dowd MK; Wan PJ; Sugimoto Y; Lin YC
Anticancer Res; 2007; 27(1A):107-16. PubMed ID: 17352222
[TBL] [Abstract][Full Text] [Related]
35. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
Akman SA; Forrest G; Chu FF; Esworthy RS; Doroshow JH
Cancer Res; 1990 Mar; 50(5):1397-402. PubMed ID: 2406012
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.
Shi Z; Liang YJ; Chen ZS; Wang XH; Ding Y; Chen LM; Fu LW
Oncol Rep; 2007 Apr; 17(4):969-76. PubMed ID: 17342344
[TBL] [Abstract][Full Text] [Related]
37. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids.
Fu LW; Deng ZA; Pan QC; Fan W
Anticancer Res; 2001; 21(4A):2273-80. PubMed ID: 11724282
[TBL] [Abstract][Full Text] [Related]
38. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
Chen G; Zeller WJ
Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
[TBL] [Abstract][Full Text] [Related]
39. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
40. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
